Background: Evaluation of the activity of the exudative form of age-related macular degeneration (AMD) during anti-vascular endothelial growth factor (anti-VEGF) therapy before and after administration of BNT162b2 (Pfizer/BioNTech) vaccination.
Methods: The optical coherence tomography and best corrected visual acuity (BCVA) records of the two previous visits before the first dose of BNT162b2 (first pre-vaccination visit marked as "V-1", the previous pre-vaccination "V-2"), and two subsequent visits after the second dose of vaccination (first visit after the second dose marked as "V1", second visit after the second dose marked as "V2") were collected for 63 eyes of 59 patients.
Results: The difference in the average retinal thickness was observed between the last and each other checkpoint for the aflibercept group and in the overall outcome. The maximum thickness from the inner retinal surface to the inner border of RPE decreased during the observation; differences were observed comparing visits -2 and 1. Subretinal complex thickness decreased during follow-up, and the differences were observed between visits -2 and 2. There were no statistically significant differences in the BCVA and the occurrence of intraretinal cystoid fluid, serous PED, subretinal hyperreflective material, and retinal hemorrhage.
Conclusion: In the present study, the activity of the exudative form of AMD did not deteriorate after the administration of the BNT162b2 vaccine.
Keywords: BNT162b2; COVID-19; age-related macular degeneration; vaccine.